OBJECTIVES: Monitoring antiretroviral treatment (ART) outcomes is essential for assessing the success of HIV care and treatment programs in resource-limited settings (RLS). METHODS: Longitudinal analyses of clinical and immunologic parameters in HIV-infected adults initiated on ART between November 2004 and June 2008 at Management and Development for Health (MDH)-Presidents Emergency Plan For AIDS Relief PEPFAR supported HIV care and treatment clinics in Tanzania. RESULTS: A total of 12 842 patients were analyzed (65.9% female, median baseline CD4 count, 106 cells/mm(3)). Significant improvements in immunologic status were observed with an increase in CD4 count to 298 (interquartile range [IQR] 199-416), 372 (256-490) and 427 (314-580) cells/mm(3), at 1, 2, and 3 years, respectively. Overall mortality was 13.1% (1682 of 12 842). Male sex, World Health Organization (WHO) stage III/IV, CD4 <200 cells/mm(3), hemoglobin (Hgb) <8.5 g/dL, and stavudine (d4T)-containing regimens were independently associated with early and overall mortality. CONCLUSIONS: Closer monitoring of males and patients with advanced HIV disease following ART initiation may improve clinical and immunologic outcomes in these individuals.
OBJECTIVES: Monitoring antiretroviral treatment (ART) outcomes is essential for assessing the success of HIV care and treatment programs in resource-limited settings (RLS). METHODS: Longitudinal analyses of clinical and immunologic parameters in HIV-infected adults initiated on ART between November 2004 and June 2008 at Management and Development for Health (MDH)-Presidents Emergency Plan For AIDS Relief PEPFAR supported HIV care and treatment clinics in Tanzania. RESULTS: A total of 12 842 patients were analyzed (65.9% female, median baseline CD4 count, 106 cells/mm(3)). Significant improvements in immunologic status were observed with an increase in CD4 count to 298 (interquartile range [IQR] 199-416), 372 (256-490) and 427 (314-580) cells/mm(3), at 1, 2, and 3 years, respectively. Overall mortality was 13.1% (1682 of 12 842). Male sex, World Health Organization (WHO) stage III/IV, CD4 <200 cells/mm(3), hemoglobin (Hgb) <8.5 g/dL, and stavudine (d4T)-containing regimens were independently associated with early and overall mortality. CONCLUSIONS: Closer monitoring of males and patients with advanced HIV disease following ART initiation may improve clinical and immunologic outcomes in these individuals.
Authors: Kosuke Kawai; Claudia A Hawkins; Ellen Hertzmark; Joel M Francis; David Sando; Aisa N Muya; Nzovu Ulenga; Wafaie W Fawzi Journal: Am J Trop Med Hyg Date: 2018-01-04 Impact factor: 2.345
Authors: Ramadhani A Noor; Ajibola I Abioye; Ellen Hertzmark; Anne M Darling; Said Aboud; Ferdinand M Mugusi; Christopher R Sudfeld; Donna Spiegelman; Wafaie W Fawzi Journal: J Nutr Date: 2020-09-01 Impact factor: 4.798
Authors: Christopher R Sudfeld; Sylvia Kaaya; Nilupa S Gunaratna; Fedinand Mugusi; Wafaie W Fawzi; Said Aboud; Mary C Smith Fawzi Journal: AIDS Date: 2017-01-14 Impact factor: 4.177
Authors: Bradley W Byers; Douglas Drak; Tinei Shamu; Cleophas Chimbetete; Rumbi Dahwa; David M Gracey Journal: AIDS Res Ther Date: 2022-05-28 Impact factor: 2.846
Authors: Christopher R Sudfeld; Ashley Buchanan; Nzovu Ulenga; Donna Spiegelman; Expeditho Mtisi; Ellen Hertzmark; Aisa N Muya; David Sando; Ester Mungure; Mucho Mizinduko; Wafaie W Fawzi Journal: AIDS Date: 2019-01-27 Impact factor: 4.177
Authors: Nora M McCormick; Nan Li; David Sando; Aisa Muya; Karim P Manji; Rodrick Kisenge; Christopher Duggan; Guerino Chalamilla; Wafaie W Fawzi; Donna Spiegelman Journal: J Acquir Immune Defic Syndr Date: 2015-11-01 Impact factor: 3.731
Authors: Paul Petraro; Christopher Duggan; Donna Spiegelman; Ellen Hertzmark; Abel Makubi; Guerino Chalamilla; Helen Siril; David Sando; Said Aboud; Wafaie W Fawzi Journal: Am J Trop Med Hyg Date: 2015-12-14 Impact factor: 2.345
Authors: Sarah W Beckham; Chris Beyrer; Peter Luckow; Meg Doherty; Eyerusalem K Negussie; Stefan D Baral Journal: J Int AIDS Soc Date: 2016-11-08 Impact factor: 5.396